Literature DB >> 15272060

Influence of normal microbiota on some aspects of the immune response during experimental infection with Trypanosoma cruzi in mice.

Rinaldo Duarte1, Andréia M Silva1, Leda Q Vieira1, Luiz Carlos C Afonso1, Jacques R Nicoli1.   

Abstract

To study the influence of normal associated microbiota on systemic immunological responses during experimental Chagas' disease, germ-free and conventional NIH Swiss mice were infected with Y strain of Trypanosoma cruzi. Although no statistical differences in mortality and parasitaemia were found, conventional mice showed IFN-gamma, TNF-alpha and NO production (P < 0.05) by spleen cell cultures and higher blood levels of immunoglobulins of the IgG2a isotype (P < 0.05) when compared to their germ-free counterparts. Moreover, higher levels of IgG1 were also found in conventional animals. On the other hand, no differences in IL10 production were found between germ-free and conventional mice after infection (P < 0.05). Interestingly, spleen cell cultures from non-infected germ-free mice spontaneously produced higher levels of IL10 than cultures from conventional mice. Moreover, cultures from non-infected germ-free mice responded to T. cruzi antigens with IFN-gamma production, contrary to cultures from conventional animals. In conclusion, the presence of the normal microbiota skews the immune response towards production of inflammatory cytokines during experimental infection with T. cruzi in mice. However, the increase in production of cytokines that is linked to resistance to this parasite did not alter the outcome of infection significantly, probably due to high virulence of the Y strain. Copyright 2004 SGM

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272060     DOI: 10.1099/jmm.0.45657-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

Review 1.  Gut microbiome and anticancer immune response: really hot Sh*t!

Authors:  S Viaud; R Daillère; I G Boneca; P Lepage; P Langella; M Chamaillard; M J Pittet; F Ghiringhelli; G Trinchieri; R Goldszmid; L Zitvogel
Journal:  Cell Death Differ       Date:  2014-05-16       Impact factor: 15.828

2.  Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands.

Authors:  Thomas B Clarke
Journal:  Infect Immun       Date:  2014-08-18       Impact factor: 3.441

Review 3.  HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets.

Authors:  Kishanda Vyboh; Mohammad-Ali Jenabian; Vikram Mehraj; Jean-Pierre Routy
Journal:  J Immunol Res       Date:  2015-02-22       Impact factor: 4.818

Review 4.  Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Authors:  Richard Greil; Evelyn Hutterer; Tanja Nicole Hartmann; Lisa Pleyer
Journal:  Cell Commun Signal       Date:  2017-01-19       Impact factor: 5.712

5.  Experimental Chagas disease-induced perturbations of the fecal microbiome and metabolome.

Authors:  Laura-Isobel McCall; Anupriya Tripathi; Fernando Vargas; Rob Knight; Pieter C Dorrestein; Jair L Siqueira-Neto
Journal:  PLoS Negl Trop Dis       Date:  2018-03-12

Review 6.  Novel cancer therapy targeting microbiome.

Authors:  Tatsuya Nagano; Takehiro Otoshi; Daisuke Hazama; Tatsunori Kiriu; Kanoko Umezawa; Naoko Katsurada; Yoshihiro Nishimura
Journal:  Onco Targets Ther       Date:  2019-05-13       Impact factor: 4.147

Review 7.  Development and Functions of the Infant Gut Microflora: Western vs. Indian Infants.

Authors:  Lalit Bharadia; Neha Agrawal; Nandan Joshi
Journal:  Int J Pediatr       Date:  2020-05-07

Review 8.  Targeting the Gut Microbiota in Chagas Disease: What Do We Know so Far?

Authors:  Eduardo Duarte-Silva; Livia H Morais; Gerard Clarke; Wilson Savino; Christina Peixoto
Journal:  Front Microbiol       Date:  2020-12-10       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.